Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III-IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of adjuvant nivolumab in patients with resected melanoma in France.
Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III-IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of adjuvant nivolumab in patients with resected melanoma in France.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Dermatol Ther (Heidelb)
Why it surfaced
Matched watchlist topic 'Novel therapeutics: immunotherapy, CAR-T, targeted therapy'. Study design: Randomized Controlled Trial (inferred). Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.